BMRN vs REGN: How BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases and Regeneron Pharmaceuticals Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BMRN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMRN and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMRN and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases, a niche where it has decades of experience. Its commercial base includes enzyme replacement therapies (Vimizim, Naglazyme, Palynziq and others) for lysosomal and metabolic disorders, plus Voxzogo, an injectable for children with achondroplasia that has become the company's fastest-growing product. In April 2026 BioMarin closed its roughly $4.8 billion all-cash acquisition of Amicus Therapeutics, adding Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease to the portfolio. Separately, the company decided to withdraw its Roctavian hemophilia gene therapy from the market after failing to find a buyer, taking an asset write-down.

Full BMRN guide

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.

Full REGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMRN drivers: Voxzogo growth engine; Amicus acquisition and portfolio breadth.
• REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. For REGN, the clearest risk is Eylea biosimilar erosion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMRN if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMRN and REGN guides.

BMRN. BioMarin posted record 2025 revenue of about $3.2 billion and raised its 2026 revenue guidance to roughly $3.83 to $3.93 billion after adding the Amicus products, implying around 20 percent growth at the midpoint. Non-GAAP EPS guidance for 2026 was trimmed slightly to about $4.85 to $5.05 to reflect near-term dilution from the acquisition. Reported trailing GAAP multiples look elevated versus biotech peers, so the story depends on the guided growth materializing.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.

Headline figures (approximate, JULY 2026): BMRN shows revenue (2025) ~$3.2B, 2026 revenue guidance ~$3.83B to $3.93B, q1 2026 revenue ~$766M, q1 2026 non-gaap eps ~$0.76; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.

BMRN and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMRN and REGN exposure against your real portfolio. It is not an investment adviser.